Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 28, 2007 Brian Lawler	No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news.
The Motley Fool October 31, 2006 Brian Lawler	Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note.
The Motley Fool June 9, 2008 Brian Lawler	Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note.
The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
The Motley Fool April 28, 2005 Stephen D. Simpson	Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical.
The Motley Fool August 8, 2008 Brian Lawler	Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest.
The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool September 30, 2008 Brian Lawler	Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
The Motley Fool October 31, 2008 Brian Orelli	Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales..
The Motley Fool January 26, 2010 Brian Orelli	Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug.
The Motley Fool January 28, 2005 Stephen D. Simpson	An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool June 18, 2010 Brian Orelli	Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
The Motley Fool April 30, 2008 Brian Lawler	A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers.
The Motley Fool December 12, 2008 Brian Orelli	Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool July 8, 2011 Brian Orelli	Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues.
The Motley Fool June 11, 2008 Brian Orelli	Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals.
The Motley Fool June 9, 2011 Brian Orelli	XOMA Breaks Bad News to Investors XOMA 052 continues to be a disaster in diabetes.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool April 20, 2010 Brian Orelli	Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be.
The Motley Fool October 19, 2006 Brian Lawler	Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
The Motley Fool October 22, 2008 Brian Orelli	Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent.
The Motley Fool August 12, 2005 Stephen D. Simpson	Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool November 5, 2008 Brian Orelli	A Byetta Beating The FDA gives Amylin and Alkermes a smack down, but neither company is knocked out yet.
The Motley Fool July 22, 2010 Brian Orelli	It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool November 1, 2007 Brian Orelli	Good News From Amylin Isn't Good Enough Investors aren't impressed by Amylin's extended-release version of Byetta, worrying that the drug may be reaching market saturation.
The Motley Fool October 20, 2010 Brian Orelli	There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon.
The Motley Fool March 3, 2011 Brian D. Pacampara	Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.
The Motley Fool August 19, 2008 Brian Orelli	Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic.
Chemistry World September 24, 2012 Andrew Turley	$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
The Motley Fool April 15, 2011 Brian Orelli	Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.